Peter L. Salgo, MD: I don’t want to leave this list without the orexin antagonists. I’m going to try to pronounce this one, suvorexant. How’d I do on that one? Sanford H. Auerbach, MD: Sounds good to ...
Actelion announced the results of its proof-of-concept/dose- ranging study1 into the effect of its first-in-class orexin receptor antagonist almorexant in 147 patients with primary insomnia. Due to be ...
June 13, 2012 (Boston, Massachusetts) — The investigational dual orexin receptor antagonist suvorexant (Merck) improved sleep onset and maintenance over a 3-month treatment period in 2 pivotal phase 3 ...
Actelion and GlaxoSmithKline (GSK) to potentially co-develop and co-commercialise other orexin receptor antagonists ALLSCHWIL, SWITZERLAND and LONDON, UK - 14 July 2008 - Actelion Ltd (SWX: ATLN) and ...
Wellbeing Whisper on MSN
Surprising Sleep Clue That Could Signal Alzheimer’s Risk
Your dreams may be telling you more than you know especially if they’re taking their time in arriving. That’s the increasing ...
Tsukuba, Japan—Orexin, named after its role in feeding regulation, is a potent endogenous sleep/wake state regulator and is expected to play an essential role in controlling the cross-talk mechanism ...
MedPage Today on MSN
Novel Orexin Drug Normalizes Wakefulness in Narcolepsy Type 1
While the study only involved narcolepsy type 1, previous work has shown that orexin signaling may be deficient in other ...
(Philadelphia, PA) – Researchers at the University of Pennsylvania School of Medicine have discovered that the recently identified neurotransmitter orexin (also known as hypocretin) influences reward ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback